Loading news...
The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing amid President Donald Trump's tariff threats.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company's U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and ne.
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different.
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer RARITAN, N.J., Feb. 18, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as a monotherapy for the treatment of adults with head and neck squamous cell carcinoma that is recurrent or metastatic and human papillomavirus (HPV)-unrelated after disease progression on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
Traditional dividend stocks have long been the go-to for income investors. However, covered call ETFs have emerged as a compelling alternative, generating income through options premiums rather than waiting for quarterly dividends.
Trellus Health PLC (AIM:TRLS) shares more than doubled in Wednesday's early trade after it announced it had secured a six-month contract extension with Johnson & Johnson Health Care Systems, keeping its Trellus Elevate programme in place for patients with moderate to severely active inflammatory bowel disease who are prescribed a J&J therapy. The AIM-traded company said the agreement, first signed in January 2025, has been extended to mid-2026 on the same economic terms, including a fixed monthly management fee.
There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That's a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America's 50 states have more millionaires than others. By the process... This State Has More Millionaires Per Capita Than Any Other.
Blue-chip dividend stocks delivered mixed returns last week as investors weighed earnings reports, dividend announcements, and shifting interest rate expectations.
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer1,3-6 HORSHAM, Pa., Feb. 17, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj).
In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, dividend increases created $4.44 in additional passive dividend income.
Beirne Wealth Consulting Services LLC bought a new position in shares of Johnson and Johnson (NYSE: JNJ) during the undefined quarter, according to the company in its most recent filing with the SEC. The fund bought 3,977 shares of the company's stock, valued at approximately $738,000. Other hedge funds have also modified their
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues.
Fifth Third Bancorp boosted its position in shares of Johnson and Johnson (NYSE: JNJ) by 7.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 1,137,116 shares of the company's stock after acquiring an additional 74,377 shares during the quarter. Fifth Third Bancorp's
On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson and Johnson (NYSE: JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc baby powder for her ovarian cancer.
The plaintiff used J&J's baby powder from 1969 until 2017. She sued in 2019 and died six months later at the age of 68.
PHILADELPHIA--(BUSINESS WIRE)--A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company's baby powder products contributing to the death of a Pennsylvania woman. The jury deliberated for more than three days before returning a verdict totaling $250,000 on behalf of the estate of York, Pennsylvania, resident Gayle Emerson, who died as a result of ovarian cancer in November of 2019 after filing her lawsuit six months earlier. The verd.
A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to an attorney for plaintiffs in nationwide talc litigation against the company.
Johnson & Johnson (JNJ) stock is currently at a notable juncture. It exhibits strong momentum, up 55% in the last twelve months, and investing in it entails support for a company characterized by robust margins, healthy cash flow, a low-debt capital structure, and favorable market conditions.